This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

FDA Can't Link Tamiflu to Deaths

Updated from 10:16 a.m. EST

The Food and Drug Administration said it doesn't see a causal relationship between Gilead's (GILD - Get Report) flu drug Tamiflu and a handful of deaths among young people in Japan, based on the information it currently has.

However, the members of the agency's pediatric advisory committee did recommend that the drug's labeling be revised to include the risk of a severe skin reaction, which occurred in a number of patients using Tamiflu.

The FDA reviewed information on 12 deaths, all in Japan, including one suicide, four sudden deaths, four cases of cardiac arrest and incidents of pneumonia, asphyxiation and pancreatitis.

Tamiflu, which is marketed by Switzerland's Roche, has been getting considerable media coverage lately because it's viewed as one of the best options to fight a possible pandemic bird flu. Worries about avian flu have been on the rise because the disease has gone from birds to humans in at least five Asian nations. Japan isn't among them.

On Friday, the FDA also reviewed seven other products. The review had been planned and wasn't held specifically to address the deaths. The agency is required to review the adverse-event reports received during the first year after a drug has been granted pediatric clearance, which applies to Tamiflu.

Regarding the deaths in Japan, the FDA said in many cases, "a relationship to Tamiflu was difficult to assess because of the use of other medications, presence of other medical conditions and/or lack of adequate detail in the reports."

Episodes of abnormal behavior, hallucinations and convulsions have also been seen in children.

The FDA said a review of the available data "suggests that the increased reports of neuropsychiatric events in Japanese children are most likely related to an increased awareness of influenza-associated encephalopathy, increased access to Tamiflu in that population and a coincident period of intensive monitoring adverse events."

Several of the documented neuropsychiatric occurrences happened in children who were taking Tamiflu and herbal medications at the same time.

The FDA said it's also seeking information on possible differences in drug dosing in Japan and whether Tamiflu actually reacts differently in Japanese patients.

The now-withdrawn painkiller Vioxx, the antifungal Diflucan and the migraine medication Imitrex are among the other drugs the FDA was reviewing.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GILD $101.00 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs